Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 3/20 | 0.89 |
| ▸ | ADAMTS5 | Q9UNA0 | 2/20 | 0.81 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.72 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.70 |
| ▸ | APAF1 | O14727 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5218036 | 1.00 | AKR1B1 (0.89) | AKR1B1ADAMTS5PTPN1ENPP2APAF1 | |
| SCHEMBL20534367 | 0.91 | AKR1B1 (0.77) | AKR1B1ADAMTS5PTPN1ENPP2 | |
| SCHEMBL20534366 | 0.91 | AKR1B1 (0.77) | AKR1B1ADAMTS5PTPN1ENPP2 | |
| SCHEMBL186520 | 0.90 | ADAMTS5 (1.00) | AKR1B1ADAMTS5PTPN1 | |
| SCHEMBL245003 | 0.90 | ADAMTS5 (1.00) | AKR1B1ADAMTS5PTPN1 | |
| SCHEMBL20534413 | 0.86 | AKR1B1 (1.00) | AKR1B1PTPN1ENPP2 | |
| SCHEMBL20534415 | 0.86 | AKR1B1 (1.00) | AKR1B1PTPN1ENPP2 | |
| SCHEMBL5216898 | 0.85 | ADAMTS5 (0.89) | AKR1B1ADAMTS5PTPN1 | |
| SCHEMBL5218721 | 0.85 | ADAMTS5 (0.89) | AKR1B1ADAMTS5PTPN1 | |
| SCHEMBL5217054 | 0.85 | ADAMTS5 (0.89) | AKR1B1ADAMTS5PTPN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1313471-B1 | BENZYLIDENE THIAZOLIDINEDIONES AND THEIR USE AS ANTIMYCOTIC AGENTS | UCB SA (BE) | 2007-04-11 | — | — | EP | disclosed |
| US-7105554-B2 | Benzylidene thiazolidinediones and their use as antimycotic agents | OXFORD GLYCOSCIENCES (UK) LTD. (GB) | 2006-09-12 | — | — | US | disclosed |
| US-20040006112-A1 | Benzylidene thiazolidinediones and their use as antimycotic agents | OXFORD GLYCOSCIENCES (UK) LTD (GB) | 2004-01-08 | — | — | US | disclosed |
| EP-1313471-A1 | BENZYLIDENE THIAZOLIDINEDIONES AND THEIR USE AS ANTIMYCOTIC AGENTS | Oxford GlycoSciences (UK) Limited (GB) | 2003-05-28 | — | — | EP | disclosed |
| WO-2002017915-A1 | BENZYLIDENE THIAZOLIDINEDIONES AND THEIR USE AS ANTIMYCOTIC AGENTS | OXFORD GLYCOSCIENCES (UK) LIMITED (GB) | 2002-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006112-A1 | Benzylidene thiazolidinediones and their use as antimycotic agents | SLC5A2, OXSR1, SLC5A1 | AKR1B1 594/4885ADAMTS5 4556/4885PTPN1 1590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.